INSMED revenue surges 296% to $425.5M on BRINSUPRI launch; net loss narrows 96% to -$13.2M

Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 7, 2025 · ~2 min read

Key Changes

• high

  BRINSUPRI (brensocatib) launched in US in August 2025 and generated $515.7M in US sales during the first six months of 2026, the company's second commercial product. European Commission and UK approvals followed in November 2025 and February 2026.

  MD&A: BRINSUPRI commercial launch verify on EDGAR →
• high

  Operating loss narrowed from $312.9M to $1.5M (99.5% improvement) as BRINSUPRI revenue scaled and contingent consideration liability revaluation produced a $146.7M gain, reflecting reduced probability-weighted milestone obligations following approval.

  Notes: Operating loss & contingent consideration verify on EDGAR →
• high

  ARIKAYCE supplemental NDA submitted in July 2026 seeking label expansion to newly diagnosed MAC lung disease patients (currently approved only for refractory cases), potentially broadening the addressable patient population significantly.

  MD&A: ARIKAYCE sNDA submission verify on EDGAR →